'Watch and wait' approach often best for older patients with kidney cancer

February 13, 2013
'Watch and wait' approach often best for older patients with kidney cancer
Study finds small tumors often grow so slowly as to pose little threat, so surgery may not be needed.

(HealthDay)—Sometimes, simply watching and waiting is a safe alternative to surgery for older patients with small kidney tumors, a new study suggests.

"Physicians can comfortably tell an elderly patient, especially a patient that is not healthy enough to tolerate and , that the likelihood of dying of is low and that kidney surgery is unlikely to extend their lives," study lead author Dr. William Huang, an assistant professor of urologic oncology at NYU Medical Center, said in a news release from the (ASCO).

The findings are to be presented Saturday at an ASCO conference in New York City. Research presented at medical meetings is typically considered preliminary until published in a peer-reviewed journal.

In their study, Huang's team analyzed data from more than 8,300 patients aged 66 and older who were diagnosed with small kidney tumors (less than 1.5 inches in diameter). Of those patients, 70 percent had surgery to remove either a part of the kidney or the entire organ and 31 percent underwent surveillance with imaging such as MRI, ultrasound and CT.

Over nearly five years of follow-up, 25 percent of the patients died from all causes and three percent of the patients died of kidney cancer. The rates of kidney were the same for patients who had surgery and those who underwent surveillance.

However, the study found patients in the surveillance group had a much lower risk of death from any cause, as well as a lower risk of having such as , stroke or vascular disease.

Huang stressed, however, that some patients may still prefer a surgical approach. "Since it is difficult to identify which tumors will become lethal, who are completely healthy and have an extended , may opt for surgery," he explained.

The researchers also found that the percentage of patients with small kidney tumors who were managed with surveillance increased between 25 percent to 37 percent from 2000 to 2007. This suggests that doctors are becoming more aware that small kidney tumors may not pose a threat, even if they are cancerous, the study authors said.

Two experts working with kidney cancer patients agreed that a "watch and wait" approach may be suitable for some patients.

The study "reaffirms the growing understanding that small [kidney] masses are relatively slow growing and generally pose only a small risk especially in the elderly population," said Dr. Manish Vira, director of the fellowship program in urologic oncology at North Shore LIJ's Arthur Smith Institute for Urology, in Lake Success, N.Y.

However, he noted that "although the risk is small, it is not zero as demonstrated by the finding that 3 percent [of the patients in the study] died of kidney cancer."

"It would interesting to look at these patients to determine if there are specific risk factors that predict more aggressive behavior of these small masses," Vira said. "This would allow physicians to target treatment for those patients with small [kidney] masses who are at higher risk."

Dr. Matthew Galsky is director of genitourinary medical oncology at the Tisch Cancer Institute at Mount Sinai School of Medicine, in New York City. He said prior studies "have shown that small that are not removed grow relatively slowly (approximately 0.3-0.4 centimeters per year) and in one series, only 1 percent of such tumors spread to other places in the body."

Galsky said the new study did have some limitations— it was retrospective, looking over past data rather than the "gold standard" prospective form of trial—and the methods of surveillance (such as scans) for the patients who did not get surgery was not made clear.

Nevertheless, he said, the findings, "should allow clinicians and patients to feel more comfortable about surveillance, particularly for the 'oldest old' and those patients with multiple [other health conditions] that would make surgery especially high risk."

Explore further: Active surveillance provides a viable alternative to surgery for small kidney masses

More information: The National Kidney Foundation has more about kidney cancer.

Related Stories

Active surveillance provides a viable alternative to surgery for small kidney masses

October 17, 2012
Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery, with similar overall and cancer specific survival rates, according to a study published in the November issue of the urology ...

Kidney cancer patients do better when whole kidney is not removed

April 17, 2012
Kidney cancer patients who had only their tumor removed had better survival than patients who had their entire kidney removed, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

Mayo Clinic finds surgeon caseload, practice setting affect treatment of small kidney tumors

May 15, 2011
Patients with small kidney tumors are more likely to be offered treatment options based on surgeons' case volume and type of practice than on tumor characteristics, a Mayo Clinic study has found. Fellowship-trained surgeons ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.